高危急性早幼粒细胞白血病患者真实世界队列中三氧化二砷与化疗诱导治疗的比较
该真实世界队列研究纳入2010至2021年法国12家医院收治的135例高危急性早幼粒细胞白血病患者,比较全反式维甲酸联合三氧化二砷(ATRA-ATO)与联合化疗(ATRA-CHT)诱导治疗的结局。ATRA-ATO组完全缓解率90%、CHT组76%(p=0.052),5年总生存率ATRA-ATO组89.86%显著高于CHT组72.69%(p=0.035)。
要点
- ATRA-ATO组完全缓解率90%,CHT组76%,差异未达统计学显著(p=0.052)。
- ATRA-ATO组5年总生存率89.86%,显著高于CHT组的72.69%(p=0.035)。
- 作者认为ATRA与ATO联合在该高危APL真实世界队列中有效且安全。
核心结论
- 在高危急性早幼粒细胞白血病真实世界队列中,ATRA与ATO联合诱导治疗有效且安全。
- 作者提及即将开展的APOLLO试验(直接比较ATRA-ATO与ATRA-CHT)结果可能验证本研究发现。
研究设计与样本
- 真实世界队列研究,纳入2010至2021年法国12家医院收治的135例高危急性早幼粒细胞白血病患者。
- 高危定义为白细胞计数≥10×10⁹/L。
- 50例(37%)接受ATRA-ATO诱导治疗(通常需联合细胞减灭治疗),85例接受标准ATRA-CHT诱导治疗(CHT组)。
主要发现
- 完全缓解率ATRA-ATO组为90%,CHT组为76%(p=0.052)。
- 5年总生存率ATRA-ATO组为89.86%(95%CI:81.81-98.70),CHT组为72.69%(63.30-83.47),p=0.035,ATRA-ATO组显著更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Front-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce. The objective for the present real-world cohort study was to assess the outcomes in 135 HR APL patients treated with ATRA-CHT or ATRA-ATO during induction at 12 French hospitals between 2010 and 2021. Of the 135 patients, 50 (37%) received ATRA-ATO as induction therapy (though combination with cytoreductive treatment was usually necessary), and 85 received standard ATRA-CHT ("CHT group"). The complete response rates were 90% in the ATRA-ATO group and 76% in the CHT group (p = 0.052). The five-year overall survival (OS) rate was significantly higher in the ATRA-ATO group (89.86% [95% confidence interval: 81.81-98.70]) than in the CHT group (72.69% [63.30-83.47]; p = 0.035). The combination of ATRA and ATO was effective and safe in this large, real-world cohort of HR APL patients. The forthcoming results of the APOLLO trial (a direct comparison of ATRA-ATO with ATRA-CHT) might validate our present findings.
引用
- Lebon D, Da Rocha A, Cassinat B, et al. Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia. Leukemia. 2025. PMID: 40555732. doi:10.1038/s41375-025-02663-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。